Yuhan Corporation
000100
株式のランク
#3833
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
株価
$63.22
時価総額
$4.27B
変化（1日）
-3.12%
変化（1年）
-23.57%
国
KR
取引 Yuhan Corporation (000100)
カテゴリー
Healthcare
Yuhan Corporation（000100）の利益
Jun 2026 時点の利益 TTM: $205.87M
Yuhan Corporation の最新の財務報告によると、同社の現在の利益は $205.87M です。2024 年には $41.79M の利益を上げ、これは 2023 年の利益 $104.14M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Yuhan Corporation の利益の推移（2007 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $205.87M | 33.56% |
| 2025 | $154.14M | 268.88% |
| 2024 | $41.79M | -59.88% |
| 2023 | $104.14M | 38.44% |
| 2022 | $75.22M | -29.06% |
| 2021 | $106.03M | -52.01% |
| 2020 | $220.97M | 364.61% |
| 2019 | $47.56M | -40.76% |
| 2018 | $80.28M | -40.96% |
| 2017 | $135.98M | -19.98% |
| 2016 | $169.93M | 18.62% |
| 2015 | $143.25M | 35.02% |
| 2014 | $106.09M | 4.27% |
| 2013 | $101.75M | 1.19% |
| 2012 | $100.55M | 9.06% |
| 2011 | $92.20M | -27.70% |
| 2010 | $127.53M | 8.26% |
| 2009 | $117.80M | 4.84% |
| 2008 | $112.36M | 0.30% |
| 2007 | $112.02M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $3.62B | 1,657.37% |
DE
|
|
| $3.40B | 1,553.97% |
DE
|
|
| $1.72B | 737.24% |
JP
|
|
| $930.30M | 351.89% |
CH
|
|
| $1.69B | 722.21% |
IN
|
